Document is current

Article History

Received: 11 September 2025

Accepted: 22 December 2025

First Online: 7 February 2026

Declarations

:

: Informed consent was obtained from all individual participants included in the study. All participants agreed to publication.

: The study was approved by the local institutional review board of the University of Duisburg-Essen, Germany (registry number: 19-8798-BO). The observational trial is registered at clinicaltrials.gov (NCT07154381).

: This work was funded by a research grant from Pfizer to C. Rischpler. D. Kersting. D. Kersting reports a research grant from Pfizer, personal fees from GE Healthcare and Novartis, travel grants from Life Molecular Imaging and Sanofi and speaker honoraria from Pfizer, outside the submitted work.. C. Rischpler reports a research grant from Pfizer. T. Hagenacker received speaker and advisory fees from Alnylam and AstraZeneca. W.P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Perceptive (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker, consultant), Eczacıbaşı Monrol (speaker), Abx (speaker), Amgen (speaker), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding) outside of the submitted work. B.M. Schaarschmidt received a research grant from PharmaCept GmbH for an investigator-initiated study not related to this paper, travel grant form Bayer AG and speaker honorarium from AstraZeneca. S. Wernhart has received honoraria for lectures from Bristol-Myers Squibb, not related to this study. The other authors have nothing to disclose.